Physiologically Based Pharmacokinetics

(M-018) Construction of a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model to Facilitate the Design of LNP based mRNA Therapeutics for Secreted Protein Targets with Applications to Anti-Viral Therapies

(M-023) Towards uncertainty assessment-based acceptability thresholds for model validation?

(M-038) Evaluation of Azithromycin Disposition in Pregnant Women Undergoing Cesarean Delivery – A Population-Based PBPK Modeling Approach

(M-039) A Physiologically Based Pharmacokinetic Framework for Predicting Drug Exposure in the Female Reproductive Tract

(M-062) Utilizing MechDermA model for early feasibility analysis in topical drug discovery

(M-075) From hot to cold: Modeling radiocopper kinetics in Wilson’s Disease to simulate cold copper endpoints

(S-021) Development of a Physiologically Based Infection Kinetic Model to Assess Bacterial Clearance by Various Immunocompromised Mouse Strains Used as Infection Models for Mycobacterium abscessus

(S-022) Dose Optimization of Inhaled Tigecycline in Humans to Overcome Inherent Adverse Events and Maximize Bacterial Clearance Using a PBPK Modeling Approach

(S-037) Mechanism-based PBPK Modeling Reveals Nonlinear Brain Pharmacokinetics of Fluvoxamine: Roles of Active Influx and Brain Metabolism

(S-038) A Physiologically Based Pharmacokinetic Model of Ceftriaxone in Healthy Adults and Pregnant Women

(S-051) First-In-Human TBD11 dose range prediction through a multispecies minimal PBPK model

(S-052) Update on Current Status of PBPK Modeling Application in Hepatic Impairment Populations: Recent Successes & Knowledge Gaps

(S-064) Physiologically Based Pharmacokinetic Modeling of Quizartinib to Assess Drug-Drug Interaction as an Inhibitor of Breast Cancer Resistance Protein

(S-065) Performance Verification and Application of Endogenous Biomarker Coproporphyrin I in the Simcyp™ Simulator V23

(S-079) Osimertinib optimal dosing through population pharmacokinetics in virtual patients with NSCLC

(S-088) A pediatric PBPK model of atropine gel to predict atropine levels in children with neurological disorders after administration to oral cavity

(S-117) Predicting Clinical Mosunetuzumab CD20 Receptor Occupancy using a Minimal Physiologically–Based Pharmacokinetic (mPBPK) Modeling Approach

(T-006) Translational two-pore PBPK model to characterize whole-body disposition of different-size oligonucleotide therapeutics

(T-010) Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies

(T-014) ACS-SIMULATOR: A Shiny Application for Guiding Antenatal Corticosteroid Administration in Pregnant Women

(T-027) Drug-drug interactions while breastfeeding with mother/infant medications: What's safe?

(T-036) Leveraging PBPK Modeling for Bioavailability Enhancement: Insights from In Vitro Dissolution and Cocrystallization Studies

(T-037) Investigating tissue distribution of curcumin using Physiologically-based pharmacokinetic (PBPK) approach

(T-045) 89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism

(T-054) Retrospective analysis of systemic and dermal PK of several anti-inflammatory topicals using SimCYP MechDermA model explains the observed clinical efficacy of successful and failed drugs

(T-055) Prospective Physiologically Based Pharmacokinetic Modeling Predictions of First-in-Patient Study PK: Examples and Application

(T-086) PK/PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer

(T-115) Quantitative investigation of ATP switch concept of STA551 by combined in vivo tissue distribution study and physiologically-based pharmacokinetic modeling